PUBLIC COMPANY
save$ANTXAN2 Therapeutics, Inc.
$ANTXMenlo Park, CA, USupdated 2mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease
- phase1First-in-Human Trial of Oral AN2-502998
- —An Observational Study to Evaluate Clinical Characteristics of Adult Patients With Suspected or Confirmed Melioidosis
- phase1Phase 1 Study of Epetraborole Tablets
- phase1A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects
Insider activity
source: SEC Form 4routine RSU / option mechanics (3)
- Apr 10, 26grantAziz Kabeer · director3,775 sh
- Apr 10, 26grantMarks Gilbert Lynn · director3,775 sh
- Apr 10, 26grantMartin Patricia A. · director1,192 sh
🐶 Hiring Signal
News
- Chutes & Ladders—Vivace revs up C-suite ahead of pivotal pushVivace Therapeutics has named Craig Gibbs, Ph.D., as its new president and CEO.fiercebiotech · 1mo ago
Data sources
last refreshed 55m ago
Found something off?
comments(0)
5-min edit window · permanent after that